

Case Study: ICERs

! Important

Please note that you can download PDF and Microsoft Word versions of this case study using the links on the right.

Case 1 Description

You seek to explore different drug strategies to treat HIV infection. Single agent therapy with retrocyclovir at 200mg per day has a mean discounted lifetime cost of \$20,000 and results in a quality-adjusted life expectancy of 70 years. Single agent therapy with retrocyclovir at 400mg per day has a mean discounted lifetime cost of \$22,000 and a quality adjusted life expectancy of 65 years (given the increased incidence of side effects with the higher dose). Another drug, centroflexavir (which comes only in one dose of 250 mg/day) has a mean total lifetime cost of \$10,000 and a quality-adjusted life expectancy of 50 years. The combination of centroflexavir with low-dose retrocyclovir has a mean-life time cost of \$40,000 and an average quality adjusted life expectancy of 80 years, while the combination of centroflexavir with high-dose retrocyclovir has a mean lifetime cost of \$35,000 and a quality-adjusted life expectancy of 75 years.

Newer ARTs are also available and their lifetime costs/QALYs are detailed below:

Table 1: Cost and QALY Outcomes for ARTs

	Cost	QALY
ART 1/2	11,000	63.4
ART 1	15,525	73.52

Instructions

Perform a cost-effectiveness analysis of the treatment options using QALYs as the measure of health effects. Which strategy would you choose and why, if the willingness-to-pay threshold is \$50,000 per quality-adjusted life year?

Treatment	Costs	QALYs
Do nothing	36,000	43.8
ART 1	15,525	73.52
ART 1/2	11,000	63.4
Retro 200	20,000	70.0
Retro 400	22,000	65.0
Centro	10,000	50.0
Centro / Retro 200	40,000	80.0
Centro / Retro 400	35,000	75.0

Table 3: Treatment Options

Strategy	Discounted Costs	Discounted QALYs	Incremental Costs	Incremental QALYs	ICER (\$/QALY)
----------	---------------------	---------------------	----------------------	----------------------	-------------------

Table 4: ICER Calculation Table 1

Strategy	Discounted Costs	Discounted QALYs	Incremental Costs	Incremental QALYs	ICER (\$/QALY)
----------	---------------------	---------------------	----------------------	----------------------	-------------------

Strategy	Discounted Costs	Discounted QALYs	Incremental Costs	Incremental QALYs	ICER (\$/QALY)

Table 5: ICER Calculation Table 2

Strategy	Discounted Costs	Discounted QALYs	Incremental Costs	Incremental QALYs	ICER (\$/QALY)
----------	---------------------	---------------------	----------------------	----------------------	-------------------

: ICER Calculation Table 3 {tbl-colwidths="[20,20,20,20,20,20]"}

Case 2 Description

You are interested in performing a cost-effectiveness analysis of different cancer screening recommendations for anal squamous intraepithelial lesions and anal cancer in men.

Below is a table of the costs and quality-adjusted life years gained associated with different screening strategies over a six-year time span.

Instructions

Calculate incremental cost-effectiveness ratios for each strategy and determine which screening strategy you would choose if, as a decision maker, you were prepared to pay \$50,000/QALY (using discounted quality-adjusted life years)

Table 6: Cost and QALY Outcomes, by Strategy

Screening Strategy	Discounted QALYs	Discounted Costs (\$2022)
No screening	10.05	4,130
Every 3 years	10.798	5,178

Screening Strategy	Discounted QALYs	Discounted Costs (\$2022)
Every 2 years	10.830	5,583
Every 1 year	10.973	6,417
Every 6 months	10.988	8,744

Table 7: ICER Calculation Table 1

Strategy	Discounted Costs	Discounted QALYs	Incremental Costs	Incremental QALYs	ICER (\$/QALY)
----------	------------------	------------------	-------------------	-------------------	----------------

Table 8: ICER Calculation Table 2

Strategy	Discounted Costs	Discounted QALYs	Incremental Costs	Incremental QALYs	ICER (\$/QALY)
----------	------------------	------------------	-------------------	-------------------	----------------